CareDx reported second quarter 2026 revenue of $132 million, a 52% year-over-year increase, driven by Testing Services revenue growth of 61% to $100 million. The company raised its full-year 2026 revenue guidance to $490–$500 million and adjusted EBITDA guidance to $66–$78 million. GAAP net income was $111 million, including a $113 million gain from the divestiture of its Lab Products business to Eurobio Scientific on June 30, 2026. Concurrently, CareDx completed the acquisition of Naveris. The company also announced that CMS finalized Medicare coverage policies for AlloSure and AlloMap. CareDx operates in the precision medicine diagnostics industry, providing molecular testing solutions for transplant, specialty oncology, and cell therapy.

CareDx, Inc. completed the sale of its Swedish subsidiary, CareDx AB, and related kitted laboratory products business to Eurobio Scientific S.A. for $171.7 million in cash. Additionally, the company completed the acquisition of Naveris, Inc. for $161.8 million in cash, with potential for up to $100.0 million in additional milestone-based cash consideration. CareDx, Inc. is a healthcare technology company specializing in transplant organ and transplant recipient monitoring solutions.